Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Talazoparib |
Synonyms | |
Therapy Description |
Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations, and in combination with Xtandi (enzalutamide) in patients with homologous recombination repair gene (ATM, ATR, BRCA1/2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C)-mutated metastatic castration-resistant prostate cancer (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Talazoparib | Talzenna | BMN673 | PARP Inhibitor (Pan) 31 | Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations, and in combination with Xtandi (enzalutamide) in patients with homologous recombination repair gene (ATM, ATR, BRCA1/2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C)-mutated metastatic castration-resistant prostate cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
DNMT3A loss | acute myeloid leukemia | resistant | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, mouse acute myeloid leukmia cells harboring DNMT3A loss along with a FLT3-ITD mutation were resistant to Talzenna (talazoparib) in culture (PMID: 34215619). | 34215619 |
IDH1 mutant | acute myeloid leukemia | predicted - sensitive | Talazoparib | Preclinical - Patient cell culture | Actionable | In a preclinical study, cells from a patient with acute myeloid leukemia harboring an IDH1 mutation were sensitive to treatment with Talzenna (talazoparib) in culture, demonstrating decreased colony formation (PMID: 29339439). | 29339439 |
IDH2 mutant | acute myeloid leukemia | predicted - sensitive | Talazoparib | Preclinical - Patient cell culture | Actionable | In a preclinical study, cells from a patient with acute myeloid leukemia harboring an IDH2 mutation were sensitive to treatment with Talzenna (talazoparib) in culture, demonstrating decreased colony formation (PMID: 29339439). | 29339439 |
IDH1 R132H | Advanced Solid Tumor | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Talzenna (talazoparib)-induced growth inhibition in culture (PMID: 28148839). | 28148839 |
PTEN loss | Advanced Solid Tumor | no benefit | Talazoparib | Phase II | Actionable | In a Phase II trial, Talzenna (talazoparib) treatment resulted in limited clinical benefit in patients with advanced solid tumors harboring PTEN deleterious mutations or loss (by IHC), with a clinical benefit rate of 9.4% (1/14, 1 with stable disease >/=24 weeks) and a median overall survival of 8.5 months and a median progression-free survival of 7.7 weeks (PMID: 39085400; NCT02286687). | 39085400 |
IDH1 R132H | colorectal cancer | predicted - sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, colorectal cancer cells harboring IDH1 R132H were sensitive to treatment with Talzenna (talazoparib) in culture, demonstrating decreased colony formation (PMID: 29339439). | 29339439 |
ATM mutant | Advanced Solid Tumor | predicted - sensitive | Talazoparib | Phase II | Actionable | In a Phase II trial (TAPUR), Talzenna (talazoparib) treatment resulted in a disease control rate of 41% and an objective response rate of 7% in advanced solid tumor patients harboring ATM mutation (n=28) or deletion (n=1) with 1 partial response in a thyroid cancer patient and 1 partial response in a lung cancer patient ongoing at 73 weeks (Cancer Res (2025) 85 (8_Supplement_2): CT228). | detail... |
IDH1 R132C | high grade glioma | sensitive | Talazoparib | Preclinical - Patient cell culture | Actionable | In a preclinical study, patient-derived glioma cells harboring IDH1 R132C demonstrated increased sensitivity to Talzenna (talazoparib)-induced growth inhibition in culture (PMID: 28148839). | 28148839 |
ATM dec exp | breast cancer | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, knockdown of ATM expression sensitized breast cancer cells to treatment with Talzenna (talazoparib) in culture (PMID: 23881923). | 23881923 |
IDH1 R132H | high grade glioma | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited viability of immortalized astrocytes expressing IDH1 R132H in culture (PMID: 34118569). | 34118569 |
IDH1 R132H | high grade glioma | sensitive | Talazoparib | Preclinical - Patient cell culture | Actionable | In a preclinical study, patient-derived glioma cells harboring IDH1 R132H demonstrated increased sensitivity to Talzenna (talazoparib)-induced growth inhibition in culture (PMID: 28148839). | 28148839 |
TET2 loss | acute myeloid leukemia | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) decreased colony formation in mouse acute myeloid leukemia cells harboring TET2 loss along with a FLT3-ITD mutation in culture (PMID: 34215619). | 34215619 |
DNMT3A loss TET2 loss | acute myeloid leukemia | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) decreased colony formation in murine acute myeloid leukemia cells harboring TET2 and DNMT3A loss along with a FLT3-ITD mutation in culture (PMID: 34215619). | 34215619 |
ATM G1676fs | cholangiocarcinoma | predicted - sensitive | Talazoparib | Case Reports/Case Series | Actionable | In a Phase II trial, Talzenna (talazoparib) treatment resulted in a clinical benefit rate (CBR) of 22.8% (18/79, 1 complete and 7 partial responses, 10 with stable disease >/=24 weeks) in patients with advanced solid tumors harboring mutations in DNA damage repair genes, including a partial response lasting 16 weeks in a cholangiocarcinoma cancer patient harboring ATM G1676fs (PMID: 39085400; NCT02286687). | 39085400 |
PTEN inact mut | Advanced Solid Tumor | no benefit | Talazoparib | Phase II | Actionable | In a Phase II trial, Talzenna (talazoparib) treatment resulted in limited clinical benefit in patients with advanced solid tumors harboring PTEN deleterious mutations or loss (by IHC), with a clinical benefit rate of 9.4% (1/14, 1 with stable disease >/=24 weeks) and a median overall survival of 8.5 months and a median progression-free survival of 7.7 weeks (PMID: 39085400; NCT02286687). | 39085400 |
BRAF V600E NRAS Q61R | melanoma | sensitive | Talazoparib | Preclinical - Pdx | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited tumor growth and led to improved survival compared to controls in a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and NRAS Q61R (PMID: 37729428). | 37729428 |
PTEN Y336* | breast cancer | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cells expressing PTEN Y336* demonstrated increased sensitivity to Talzenna (talazoparib) compared to cells expressing wild-type Pten in culture (PMID: 25946202}. | 25946202 |
ATM S1599* | appendix cancer | predicted - sensitive | Talazoparib | Case Reports/Case Series | Actionable | In a Phase II trial, Talzenna (talazoparib) treatment resulted in a clinical benefit rate (CBR) of 22.8% (18/79, 1 complete and 7 partial responses, 10 with stable disease >/=24 weeks) in patients with advanced solid tumors harboring mutations in DNA damage repair genes, including a partial response lasting 12 weeks in an appendiceal cancer patient harboring ATM S1599* (PMID: 39085400; NCT02286687). | 39085400 |
PTEN negative | Advanced Solid Tumor | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, PTEN-deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor Talzenna (talazoparib) (PMID: 23881923). | 23881923 |
IDH1 R132H | colon carcinoma | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Talzenna (talazoparib)-induced growth inhibition in culture (PMID: 28148839). | 28148839 |
BRAF V600E NRAS Q61K | melanoma | sensitive | Talazoparib | Preclinical - Pdx | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited tumor growth and led to improved survival compared to controls in a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and NRAS Q61K (PMID: 37729428). | 37729428 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03395197 | Phase III | Talazoparib | Talazoparib + NHT vs. NHT Monotherapy in DDR+ mCRPC (TALAPRO-2) | Active, not recruiting | USA | SWE | POL | NZL | NOR | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 7 |
NCT02034916 | Phase II | Talazoparib | A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) | Terminated | USA | GBR | FRA | ESP | DEU | 0 |
NCT02316834 | Phase I | Talazoparib | POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer | Completed | USA | 0 |
NCT04801966 | Phase 0 | Palbociclib Alpelisib Atezolizumab Vemurafenib Ribociclib Talazoparib Cobimetinib Trametinib Abemaciclib Dabrafenib Nivolumab Binimetinib Pembrolizumab Encorafenib | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (TAILOR) | Terminated | AUS | 0 |
NCT03499353 | Phase II | Talazoparib | Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Terminated | USA | 0 |
NCT01286987 | Phase I | Talazoparib | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Completed | USA | GBR | 0 |
NCT02401347 | Phase II | Talazoparib | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | Completed | USA | 0 |
NCT04170946 | Phase I | Talazoparib | Talazoparib and Thoracic RT for ES-SCLC | Recruiting | CAN | 0 |
NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab Fexagratinib Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT06844383 | Phase II | Enzalutamide + Talazoparib Talazoparib | A Study of Talazoparib with or Without Enzalutamide in People with Prostate Cancer Who Have Previously Received Abiraterone Acetate (TALENT) | Not yet recruiting | USA | 0 |
NCT02997176 | Phase I | Talazoparib | An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) | Completed | USA | 0 |
NCT03148795 | Phase II | Talazoparib | A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer | Completed | USA | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | BRA | BEL | AUT | AUS | 1 |
NCT02326844 | Phase II | Talazoparib | BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment | Terminated | USA | 0 |
NCT01945775 | Phase III | Gemcitabine Capecitabine Vinorelbine Talazoparib Eribulin | A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA) | Completed | USA | POL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | BRA | BEL | AUS | 4 |
NCT03042910 | Phase I | Talazoparib | A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04672460 | Phase I | Talazoparib | A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT03990896 | Phase II | Talazoparib | Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Recruiting | USA | 0 |
NCT05725200 | Phase II | Dasatinib Palbociclib Gemcitabine Trastuzumab Cetuximab Pertuzumab Panobinostat Alectinib Venetoclax Larotrectinib Encorafenib Everolimus Idelalisib Crizotinib Pembrolizumab Methotrexate Talazoparib | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer (EVIDENT) | Recruiting | NOR | 0 |
NCT03964532 | Phase Ib/II | Talazoparib Avelumab + Talazoparib | TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer | Active, not recruiting | USA | 0 |
NCT04550494 | Phase II | Talazoparib | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | Recruiting | USA | 0 |
NCT06193525 | Phase II | Talazoparib | FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test (FUTURE) | Recruiting | NLD | 0 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Futibatinib Ipilimumab + Nivolumab Palbociclib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
NCT02286687 | Phase II | Talazoparib | Talazoparib in Treating Patients with Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes | Active, not recruiting | USA | 0 |
NCT02921919 | Phase II | Talazoparib | Open-Label Extension and Safety Study of Talazoparib | Completed | USA | POL | HUN | GBR | FRA | DEU | CAN | 2 |
NCT04462809 | Phase II | Talazoparib | Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO) | Unknown status | 0 | |
NCT03968406 | Phase I | Talazoparib | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | Recruiting | USA | 0 |
NCT02282345 | Phase II | Talazoparib | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer | Completed | USA | 0 |
NCT02537561 | Phase I | Talazoparib Cisplatin + Gemcitabine | Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | Withdrawn | 0 | |
NCT01989546 | Phase Ib/II | Talazoparib | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | Completed | USA | 0 |
NCT03974217 | Phase I | Talazoparib | Talazoparib for Cohesin-Mutated AML and MDS with Excess Blasts | Recruiting | USA | 0 |
NCT04756765 | Phase II | Talazoparib | Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer | Recruiting | USA | 0 |
NCT04598321 | Phase I | Talazoparib | BrUOG 390: Neoadjuvant Treatment With Talazoparib | Terminated | USA | 0 |
NCT03377556 | Phase II | Talazoparib | Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT02997163 | Phase I | Talazoparib | An Open-Label Pharmacokinetics and Safety Study of Talazoparib | Completed | USA | CAN | 0 |
NCT02567396 | Phase I | Talazoparib | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Withdrawn | 0 | |
NCT02925234 | Phase II | Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab Pemigatinib | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |
NCT05097599 | Phase II | Binimetinib + Encorafenib Trastuzumab deruxtecan Enfortumab vedotin-ejfv Talazoparib Lorlatinib | Strata PATH (Precision Indications for Approved Therapies) (Strata PATH) | Terminated | USA | 0 |